ArTara Therapeutics, Inc. 宣布，公司研发管线进展顺利，仍按照既定时间表推进关键临床试验。目前预计在2026年下半年，正式启动针对BCG初治患者群体的Advanced-3期注册临床试验。这一试验的启动是公司药物开发路径上的一个重要里程碑，标志着其核心候选产品向潜在获批上市又迈出了关键一步。
ArTara Therapeutics, Inc. 宣布，公司研发管线进展顺利，仍按照既定时间表推进关键临床试验。目前预计在2026年下半年，正式启动针对BCG初治患者群体的Advanced-3期注册临床试验。这一试验的启动是公司药物开发路径上的一个重要里程碑，标志着其核心候选产品向潜在获批上市又迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.